```html

Dural Sinus Thrombosis (Cerebral Venous Sinus Thrombosis)

Overview

Cerebral venous sinus thrombosis (CVST), also called dural sinus thrombosis, is a rare type of stroke that occurs when a blood clot forms in one of the brain’s dural venous sinuses — the channels that drain blood from the brain back toward the heart. Unlike the more common arterial strokes caused by a blockage of an artery, CVST blocks the venous side of circulation, leading to increased intracranial pressure, cerebral edema, and sometimes hemorrhage.

Who it affects: CVST can develop at any age, but it most often occurs in young to middle‑aged adults (median age 35–40 years). Women are affected 2–3 times more often than men, largely because of pregnancy, hormonal contraception, and certain gynecologic conditions.

Prevalence: In the United States, CVST accounts for approximately 0.5–1 % of all strokes, translating to about 5–10 cases per million people each year (CDC). Worldwide incidence ranges from 3 to 4 cases per million per year, with higher rates reported in regions where infectious or pro‑thrombotic diseases are common (WHO). Although rare, its potentially life‑threatening nature makes early recognition essential.

Symptoms

Symptoms of dural sinus thrombosis are often non‑specific and can evolve over hours to days. The most common presentations include:

• Headache – New‑onset, persistent, and often worse when lying down; may be diffuse or localized to the back of the head (occipital).
• Focal neurological deficits – Weakness or numbness in an arm or leg, facial droop, or difficulty speaking (aphasia).
• Seizures – New seizures (felt as convulsions or staring spells) occur in up to 40 % of patients.
• Visual disturbances – Double vision, blurred vision, or transient loss of vision caused by increased intracranial pressure.
• Papilledema – Swelling of the optic disc seen on eye examination; a sign of raised pressure.
• Nausea and vomiting – Frequently accompanies severe headache, especially when intracranial pressure rises.
• Altered mental status – Confusion, lethargy, or even coma in severe cases.
• Neck stiffness – May mimic meningitis when the clot irritates surrounding meninges.
• Focal sensory changes – Tingling or loss of sensation in a specific region.

Because many of these symptoms overlap with migraine, tension headache, or other neurologic conditions, a high index of suspicion is necessary—especially in patients with known risk factors.

Causes and Risk Factors

CVST is most often the result of a hypercoagulable (pro‑thrombotic) state, but multiple pathways can lead to clot formation within the dural sinuses.

Primary Causes

• Genetic thrombophilias – Factor V Leiden, prothrombin G20210A mutation, protein C or S deficiency, antithrombin deficiency.
• Acquired hypercoagulable conditions – Antiphospholipid antibody syndrome, malignancy (especially adenocarcinomas), nephrotic syndrome.
• Hormonal influences – Oral contraceptives, hormone replacement therapy, pregnancy, and the postpartum period (the risk peaks in the first 6 weeks after delivery).
• Infections – Central nervous system infections (e.g., meningitis, sinusitis, otitis media), facial or dental infections that spread to the venous sinuses.
• Inflammatory disorders – Behçet disease, systemic lupus erythematosus, inflammatory bowel disease.
• Trauma and neurosurgical procedures – Direct injury to the sinus or prolonged dehydration after surgery.

Additional Risk Factors

• Dehydration (common in athletes, hikers, or patients with vomiting)
• Obesity (BMI ≥ 30 kg/m² increases clotting tendency)
• Smoking
• Advanced age (though CVST is more common in younger adults, older patients have a worse prognosis)
• Use of certain medications (e.g., cyclosporine, tamoxifen)

Diagnosis

Prompt diagnosis relies on a combination of clinical suspicion, neuro‑imaging, and laboratory work‑up.

Imaging Studies

• Magnetic Resonance Venography (MRV) – First‑line non‑invasive test; visualizes lack of flow in the sinus and can detect associated brain edema or hemorrhage.
• Computed Tomography Venography (CTV) – Faster than MRV, useful in emergency settings; shows a “dense triangle” or “empty delta” sign indicating thrombus.
• Standard CT scan – May reveal hyperdense sinus (acute clot) or secondary hemorrhage, but is less sensitive for early clot detection.
• Digital Subtraction Angiography (DSA) – Invasive gold standard, reserved for cases where non‑invasive studies are inconclusive or when endovascular therapy is being planned.

Laboratory Tests

• Complete blood count, basic metabolic panel, coagulation profile (PT/INR, aPTT).
• Hypercoagulability work‑up (after acute phase): Factor V Leiden, prothrombin gene mutation, protein C/S, antithrombin, antiphospholipid antibodies.
• Inflammatory markers (ESR, CRP) if an underlying inflammatory disease is suspected.
• Pregnancy test in women of childbearing age.

Diagnostic Criteria (simplified)

1. Clinical presentation compatible with CVST (headache + focal signs, seizures, or papilledema).
2. Imaging evidence of thrombus in a dural venous sinus.
3. Exclusion of alternative diagnoses (e.g., arterial stroke, intracerebral hemorrhage unrelated to thrombosis).

Treatment Options

Treatment aims to recanalize the occluded sinus, prevent clot propagation, treat complications, and address underlying risk factors.

Anticoagulation

• Initial therapy – Low‑molecular‑weight heparin (LMWH) (e.g., enoxaparin) or unfractionated heparin, administered intravenously or subcutaneously. Studies show anticoagulation improves outcomes even when intracerebral hemorrhage is present (Mayo Clinic).
• Long‑term anticoagulation – Transition to oral anticoagulants for 3–12 months (warfarin with INR 2.0–3.0) or direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban, which are increasingly used based on recent trials.
• Duration may be extended (≥12 months) if a persistent thrombophilia or ongoing risk factor remains.

Endovascular and Surgical Options

• Mechanical thrombectomy – Catheter‑based removal of clot; reserved for patients who deteriorate despite anticoagulation.
• Local thrombolysis – Infusion of tissue plasminogen activator (tPA) directly into the sinus; benefits must be weighed against bleeding risk.
• Decompressive hemicraniectomy – Surgical removal of a portion of skull to relieve life‑threatening brain swelling; considered in fulminant cases with herniation signs.

Management of Complications

• Seizure control – Antiepileptic drugs (levetiracetam, valproate) are started if seizures occur; prophylactic use is controversial but may be considered in high‑risk lesions.
• Intracranial pressure (ICP) reduction – Head elevation, analgesia, osmotic agents (mannitol or hypertonic saline) and, if needed, ventriculostomy.
• Treatment of underlying cause – e.g., antibiotics for sinus infection, discontinuation of oral contraceptives, cancer therapy.

Lifestyle and Supportive Measures

• Hydration – Aim for >2 L fluid intake daily unless contraindicated.
• Gradual mobilization once stable to reduce venous stasis.
• Smoking cessation and weight management.
• Regular follow‑up imaging (MRV or CTV) at 3–6 months to assess recanalization.

Living with Dural Sinus Thrombosis

Many patients return to near‑normal life after appropriate treatment, but ongoing vigilance is key.

Daily Management Tips

• Medication adherence – Set daily alarms, use pill organizers, and keep a medication list for any healthcare visit.
• Monitor for new symptoms – Headache recurrence, visual changes, or weakness should prompt immediate evaluation.
• Regular follow‑up – Neurologist visits every 1–3 months during the first year, then annually if stable.
• Safe physical activity – Low‑impact aerobic exercise (walking, stationary cycling) after clearance; avoid activities with high Valsalva strain (heavy lifting) until fully recanalized.
• Nutrition – Balanced diet rich in omega‑3 fatty acids, fruits, and vegetables; limit processed foods and excess sodium.
• Vaccinations – Stay up to date, especially against influenza and COVID‑19, which can precipitate hypercoagulability.
• Psychological health – Anxiety and depression are common after stroke; consider counseling, support groups, or cognitive‑behavioral therapy.

Prevention

Because many risk factors are modifiable, preventive strategies focus on minimizing clot‑forming conditions.

• Hormonal considerations – Women with a history of CVST should discuss non‑estrogenic contraception (e.g., copper IUD) with their provider.
• Manage chronic diseases – Tight control of diabetes, hypertension, and hyperlipidemia.
• Prophylactic anticoagulation – In high‑risk situations (major surgery, prolonged immobilization, pregnancy with thrombophilia), low‑dose LMWH may be prescribed per guideline.
• Hydration – Encourage adequate fluid intake during illness, travel, or hot weather.
• Smoking cessation programs – Use nicotine replacement, counseling, or prescription aids.
• Weight control – Aim for BMI < 25 kg/m²; structured diet and exercise plans can reduce thrombosis risk.

Complications

If not recognized and treated promptly, dural sinus thrombosis can lead to serious, sometimes permanent, complications:

• Venous infarction – Brain tissue death due to impaired drainage, often hemorrhagic.
• Seizure disorder – Chronic epilepsy may develop after an initial seizure event.
• Persistent intracranial hypertension – Can cause chronic headache, visual loss, or papilledema.
• Neurological deficits – Long‑term weakness, speech problems, or cognitive impairment.
• Re‑thrombosis – Recurrence risk is higher in patients with untreated underlying thrombophilia.
• Death – Mortality rates range from 5–15 % in modern series, largely depending on speed of diagnosis and severity of brain injury (Cleveland Clinic).

When to Seek Emergency Care

---

References: Mayo Clinic, CDC, WHO, Cleveland Clinic, NIH National Institute of Neurological Disorders and Stroke, recent peer‑reviewed articles (2020‑2024) on CVST management.

```